Xiaosu Ma

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Sean Wharton, Thomas Blevins, Lisa Connery et al. · New England Journal of Medicine · 2023 · 378 citations

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

Steven E. Nissen, Helle Linnebjerg, Xi Shen et al. · JAMA · 2023 · 172 citations · Full text

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Juan P. Frías, Stanley H. Hsia, Sarah Eyde et al. · The Lancet · 2023 · 135 citations

Diabetes Management, Medicine, Diabetes +8

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

Chafiq Hamdouchi, Steven D. Kahl, Anjana Patel Lewis et al. · Journal of Medicinal Chemistry · 2016 · 58 citations · Full text

Pharmacotherapy, Insulin Signaling, Translational Pharmacology +17

Orforglipron ( <scp>LY3502970</scp> ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

Edward Pratt, Xiaosu Ma, Rong Liu et al. · Diabetes Obesity and Metabolism · 2023 · 46 citations · Full text